Enter Your Practice Information





Yes No

Yes No


X
x

Welcome to the all-new Vetlearn

  • Vetlearn is getting a new home. Starting this fall,
    Vetlearn becomes part of the NAVC VetFolio family.

    You'll have access to the entire Compendium and
    Veterinary Technician archives and get to explore
    even more ways to learn and earn CE by becoming
    a VetFolio subscriber. Subscriber benefits:
  • Over 500 hours of interactive CE Videos
  • An engaging new Community for tough cases
    and networking
  • Three years of NAVC Conference Proceedings
  • All-new articles (CE and other topics) for the entire
    healthcare team

To access Vetlearn, you must first sign in or register.

registernow

  • Registration for new subscribers will open in September 2014!
  • Watch for additional exciting news coming soon!
Become a Member

Journal November 2011 (Vol 33, Issue 11)

NOTE: You have already passed this course.
NOTE: This course is no longer valid for accreditation purposes.

Pimobendan and Its Use in Treating Canine Congestive Heart Failure by Danielle Bowles , BVSc, FANZCVS, Darren Fry , MA, VetMB, MRCVS, FANZCVS

1. Compared with extracellular levels, cardiomyocyte intracellular (cytosolic) calcium levels are ________ in diastole and ________ in systole.
2. Which statement is correct with regard to the effects of pimobendan?
3. Pimobendan’s two mechanisms of action are
4. Which statement is true with regard to the reported adverse effects of pimobendan?
5. What is the recommended dose range for pimobendan in dogs?
6. The PITCH trial found that, in dogs with CHF due to DCM or MVD,
7. Which statement regarding the studies of pimobendan in dogs with MVD is correct?
8. Which statement regarding the use of pimobendan in dogs with DCM is true?
9. What effect does pimobendan have on the RAAS?
10. Which statement is true with regard to pimobendan?
Stay on top of all our latest content — sign up for the Vetlearn newsletters.
  • More
Subscribe